INCY

Incyte Corp is a research‑driven biopharmaceutical company that discovers, develops and commercializes small‑molecule therapeutics, primarily in oncology, hematology and inflammatory diseases. Its flagship product, Jakafi (ruxolitinib), treats rare blood cancers and graft‑versus‑host disease and generates the bulk of its revenue, while newer launches such as the topical drug Opzelura expand its portfolio into dermatology. Operating within the specialty‑pharma segment, Incyte leverages a mix of direct product sales, royalty streams from partnered assets, and a robust pipeline of late‑stage candidates across cancer, immunology and dermatology, positioning it as a focused player with a strong oncology franchise and growing diversification.